Next-level technology is transforming the process from the early end of the process to later stages of clinical development. This special edition will share innovations impacting drug discovery (such as artificial intelligence and machine learning, remote...
While some diseases only impact a small percentage of the population, these unique patients still need treatments and therapies. This online event will discuss the needs of such special patients, how researchers can address recruitment and enrollment,...
While patient participants are undeniably an important component of the clinical research equation, they all too often are not considered strongly enough at the various stages of the process, starting with trial design. This online event will share reasons...
Many diseases afflict only a small percentage of the population - these patients need treatments and therapies, but they present unique challenges. This webinar will talk about the singular needs of such patients, how to address recruitment and enrollment,...
In order to keep competitive, pharma firms and their partners must keep current with the latest developments in drug delivery. This webinar will bring together leading experts from various corners of the field to discuss new innovations, enhancements...
Next-level technology is transforming the process from the early end of the process to later stages of clinical development. This webinar will share innovations impacting drug discovery (such as artificial intelligence and machine learning, remote monitoring...
This editorial webinar will explore advancements in technology that are changing the way we view clinical trials, including remote monitoring solutions, AI and more.
In this editorial webinar, we bring together leading experts to discuss what major trends are occurring across the industry in the development of new methods of drug delivery, as well as improvements to existing ones. We aim to inform the listeners of...
The term “special population” exists to protect certain vulnerable patient groups that require additional consideration as it pertains to clinical research, including women, pediatrics, and the elderly.
Artificial intelligence (AI) is the industry’s latest buzzword and is being touted as the solution to myriad problems. So where will it have the biggest impact across the drug development continuum? From identifying repurposable drugs, to mining data...
